GSK stop clinical trial of NPS PTH agent Ronacaleret

NPS Pharmaceuticals have announced that its partner GlaxoSmithKline have decided to prematurely stop a mid-stage study of PTH agent Ronacaleret in post-menopausal women with osteoporosis due to an observed lack of efficacy.

GlaxoSmithKline publish series of bombesin receptor subtype 3 agonists

GlaxoSmithKline have published a series of bombesin receptor subtype 3 agonists

Phase I data show Theravance LAMA GSK1160724/TD-4208 safe in COPD patients

Theravance have announced Phase 1 data showing its long acting muscarinic antagonist (LAMA), GSK1160724/TD-4208 to be safe and well tolerated in the treatment of chronic obstructive pulmonary disease (COPD). Partner GSK have, however, informed Theravance that it intends to return the LAMA program to Theravance because the current formulation of TD-4208 is incompatible with GSK’s [...]

Theravance annouces positive Phase II results of MABA GSK961081 in COPD

Theravance/GSK have announced positive results from a Phase II study of GSK961081 for the treatment of chronic obstructive pulmonary disease (COPD). The successful achievement of proof-of-concept in the MABA Phase 2 clinical study triggers a milestone payment of $10 million from GSK.

GlaxoSmithKline license Actelions orexin receptor antagonist almorexant

Actelion and GlaxoSmithKline have entered into exclusive collaboration for development of orexin receptor antagonist almorexant. Almorexant is currently in phase III development as a treatment for primary insomnia.

FDA approves GSKs Requip XL for Parkinsons

The FDA has approved GSKs extended release formulation of Requip (ropinirole) for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.

EPIX trigger milestone in GPCR drug discovery collaboration with GSK

EPIX Pharmaceuticals has achieved a key milestone in its collaboration with GlaxoSmithKline. EPIX has delivered a third GPCR candidate into lead optimization

GlaxoSmithKline submit NDA for casopitant in chemotherapy-induced nausea and vomiting

GlaxoSmithKline have filed a NDA for its NK-1 receptor antagonist casopitant (Rezonic, Zunrisa) for the treatment of chemotherapy-induced nausea and vomiting. Phase III results show that 86% of patients treated with casopitant demonstrated complete response rates

Exacerbations in COPD reduced with Advair

Advair Diskus 250/50 (fluticasone propionate and salmeterol) has been shown to reduce exacerbationsin Chronic Obstruvtive Pulmonary Disease (COPD) patients by 30%

ChemoCentryx Begins Phase I trial with CCR1 Inhibitor CCX354

ChemoCentryx have initiated a Phase I clinical trial of CCX354, an orally-available CCR1 receptor antagonist with potential in the treatment of rheumatoid arthritis.